Line 66: | Line 66: | ||
<br> | <br> | ||
<h3 class="heading h3">This is CAPOEIRA</h3> | <h3 class="heading h3">This is CAPOEIRA</h3> | ||
+ | </div> | ||
+ | |||
+ | |||
+ | <div class="row row-grid align-items-center"> | ||
+ | <div class="col-lg-5"> | ||
+ | <img src="https://static.igem.org/mediawiki/2018/0/01/T--EPFL--bioinfo.svg" class="img-center img-fluid" width="400px"> | ||
+ | </div> | ||
+ | <div class="col-lg-7 ml-lg-auto"> | ||
+ | <div> | ||
+ | <h3><font size="+2">Bioinformatics</font></h3> | ||
+ | <p class="lead text-gray my-4"> | ||
+ | <font size="+2">First, a bioinformatic pipeline integrating state-of-the-art tools identifies our target: melonoma neoantigens, the fingerprints of cancer cells</font> | ||
+ | </p> | ||
+ | |||
+ | </div> | ||
+ | </div> | ||
+ | </div> | ||
+ | <br> | ||
+ | <div class="row row-grid align-items-center"> | ||
+ | <div class="col-lg-5 order-lg-2 ml-lg-auto"> | ||
+ | <img src="https://static.igem.org/mediawiki/2018/b/b2/T--EPFL--vaccine-logo.svg" class="img-center img-fluid" width="400px"> | ||
+ | </div> | ||
+ | <div class="col-lg-7 order-lg-1"> | ||
+ | <div class="pr-lg-7"> | ||
+ | <h3>Vaccine</h3> | ||
+ | <p class="lead text-gray my-4">Next, cell-free protein expression rapidly synthesizes a library of encapsulin protein nanocompartments presenting the various neoantigen epitopes</p> | ||
+ | |||
+ | </div> | ||
+ | </div> | ||
+ | </div> | ||
+ | |||
+ | <div class="row row-grid align-items-center"> | ||
+ | <div class="col-lg-5"> | ||
+ | <img src="https://static.igem.org/mediawiki/2018/6/6f/T--EPFL--DC-logo.svg" class="img-center img-fluid" width="400px"> | ||
+ | </div> | ||
+ | <div class="col-lg-7 ml-lg-auto"> | ||
+ | <div> | ||
+ | <h3><font size="+2">Bioinformatics</font></h3> | ||
+ | <p class="lead text-gray my-4"> | ||
+ | <font size="+2">First, a bioinformatic pipeline integrating state-of-the-art tools identifies our target: melonoma neoantigens, the fingerprints of cancer cells</font> | ||
+ | </p> | ||
+ | |||
+ | </div> | ||
+ | </div> | ||
</div> | </div> | ||
</div> | </div> | ||
− | + | ||
− | + | ||
− | + | ||
</section> | </section> |
Revision as of 16:54, 17 October 2018
CAPOEIRA
Cancer Personalized Encapsulin Immunotherapy and Relapse Assay
Learn more about our projectWhat is CAPOEIRA ?
While Melanoma remains the deadliest form of skin cancer, immunotherapy approaches can harness our immune system to defeat it! Yet, current immuno-treatments suffer from high costs, limited accessibility, and poor specificity. Our project “CAPOEIRA”, named after the Brazilian self-defense martial-art, exploits the potential of synthetic biology to develop a personalized, cost-effective, and rapid production scheme for cancer vaccine and point-of-care relapse surveillance. First, a bioinformatic pipeline integrating state-of-the-art tools identifies our targets: melanoma neoantigens, the fingerprints of cancer cells. Next, cell-free protein expression rapidly synthesizes a library of encapsulin protein nanocompartments presenting the various neoantigen epitopes. This encapsulin vaccine activates dendritic cells which trigger T-cells’ attack on the neoantigen-bearing cancer cells. Nevertheless, we don’t underestimate a defeated villain! To detect potential relapse, we combine techniques including dumbbell probes, rolling circle amplification, isothermal amplification, and CRISPR-Cas12a to detect circulating tumor miRNA and DNA. Ultimately, CAPOEIRA trains the immune system to fight back!
This is CAPOEIRA
Bioinformatics
First, a bioinformatic pipeline integrating state-of-the-art tools identifies our target: melonoma neoantigens, the fingerprints of cancer cells
Vaccine
Next, cell-free protein expression rapidly synthesizes a library of encapsulin protein nanocompartments presenting the various neoantigen epitopes
Bioinformatics
First, a bioinformatic pipeline integrating state-of-the-art tools identifies our target: melonoma neoantigens, the fingerprints of cancer cells